Supplementary Data S1-S9 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Unknown|2023Cited by 0
Supplementary Figure S4 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Unknown|2023Cited by 0
Supplementary Figure S2 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Unknown|2023Cited by 0
Supplementary Figure S3 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Unknown|2023Cited by 0
Supplementary Tables S1-S6 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Unknown|2023Cited by 0